Tirzepatide SYNERGY-NASH MASH Liver Fibrosis Trial
The SYNERGY-NASH Phase 2 trial found tirzepatide resolved MASH without fibrosis worsening in up to 62% of participants vs. 10% for placebo.
The SYNERGY-NASH Phase 2 trial found tirzepatide resolved MASH without fibrosis worsening in up to 62% of participants vs. 10% for placebo.